Selective estrogen receptor degrader
Not to be confused with Selective estrogen receptor modulator.
A selective estrogen receptor degrader or downregulator (SERD) is a type of drug which binds to the estrogen receptor (ER) and, in the process of doing so, causes the ER to degrade and thus downregulate. Marketed SERDs include the antiestrogen (ER silent antagonist) fulvestrant and the selective estrogen receptor modulator (SERM) bazedoxifene, while SERDs that are currently under development include brilanestrant and elacestrant. SERDs are used in the treatment of ER-positive breast cancer, and are considered to be an improvement over previous, less efficacious therapies like the SERM tamoxifen.
See also
References
- Garner, F; Shomali, M; Paquin, D; Lyttle, C. R.; Hattersley, G (2015). "RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models". Anti-cancer drugs. 26 (9): 948–56. doi:10.1097/CAD.0000000000000271. PMC 4560273. PMID 26164151.
ER |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
GPER |
| ||||||||||
See also: Androgenics • Glucocorticoidics • Mineralocorticoidics • Progestogenics • Steroid hormone metabolism modulators |
This article is issued from Wikipedia - version of the 10/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.